AstraZeneca said profit and revenue streams will likely fall in 2017 as generic drugs eat into the market share of its blockbuster anti-cholesterol drug Crestor.
A bitter defeat in a U.S. patents case is the latest in a series of setbacks for Teva that has investors calling for major changes at the generic drugmaker.
Eli Lilly is looking to begin 2017 with a series of organizational changes that includes changes in some leadership roles.
Drugmaker Allergan Plc said it would buy LifeCell – a regenerative medicine unit owned by privately held Acelity LP Inc. – for $2.9 billion in cash.
Mylan NV will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.
Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.
Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli.
Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.
Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.